Abstract 16720: Cardiovascular Toxicities of Cyclin Dependent Kinase (cdk) 4/6 Inhibitors in Metastatic Breast Cancer Patients

Autor:	Jenica N. Upshaw, Michael G. Fradley, Yiqing Chen, Yan Gong, Bonnie Ky, Avirup Guha, Nam H.K. Nguyen
Rok vydání:	2020
Předmět:	biology business.industry Improved survival Cancer Atrial arrhythmias medicine.disease Metastatic breast cancer Hormone receptor Cyclin-dependent kinase Physiology (medical) medicine Cancer research biology.protein In patient Cardio oncology Cardiology and Cardiovascular Medicine business
Zdroj:	Circulation. 142
ISSN:	1524-4539 0009-7322
DOI:	10.1161/circ.142.suppl_3.16720
Popis:	Introduction: Cyclin Dependent Kinase (CDK) 4/6 inhibitors are a novel class of cancer therapeutics which have significantly improved survival in patients with hormone receptor positive, HER2 negative metastatic breast cancer. There is little data regarding the epidemiology of cardiotoxicity with these therapies. Methods: Using the OneFlorida Data Trust , adult patients without prior cardiovascular disease who received at least one CDK 4/6 inhibitor between January 1, 2012 and December 31, 2018 were included in the analysis. CAEs identified from ICD 9/10 codes include: new hypertension (HTN); arrhythmias (excluding sudden cardiac death); new hypertension (HTN); heart failure/cardiomyopathy; ischemic heart disease, pericardial disease. Log-rank tests were performed to compare time to all-cause mortality in patients with or without CAE. Multivariable cox proportional hazard regressions were performed to estimate the hazard ratio (HR) and 95% confidence interval (CI) for mortality adjusting for age, gender, race, obesity, HTN, diabetes (DM) and hyperlipidemia (HLD). Results: A total of 1,035, predominantly female (96%) patients were included in the analysis. The mean age was 61±13 years, and CV risk factors were prevalent at baseline: obesity (17.1%), HTN (22.2%), DM (9.9%), HLD (10.5%). Cardiotoxicity occurred in 174 (16.8%) patients of which 30 (17.2%) died (p Conclusions: Cardiotoxicity is common with CDK 4/6 inhibitors and are associated with overall increased mortality and arrhythmias and HTN accounting for a significant proportion of this finding. Patients taking CDK 4/6 inhibitors should be monitored for CAEs with aggressive risk mitigation strategies to minimize morbidity and mortality.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ee2dc428f3fa2d2bad366d7189b6b632 https://doi.org/10.1161/circ.142.suppl_3.16720 Zobrazit plný text záznamu